<DOC>
	<DOC>NCT00659412</DOC>
	<brief_summary>Randomized, double-blind, 24-week study of patients with psoriatic arthritis comparing alefacept + methotrexate (MTX) vs. placebo + MTX followed by a 24-week open-label extension with only alefacept + MTX treatment.</brief_summary>
	<brief_title>A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis</brief_title>
	<detailed_description>Patients who completed the initial 24-week treatment course and met the inclusion and exclusion criteria for the 24 week open-label extension continued on their stable MTX dose and also received alefacept throughout this extension.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Psoriatic arthritis MTX treatment for 3 months prior to enrollment with continuing disease Normal Tcell count Other types of psoriasis History of malignancy or lymphoproliferative disorder Serious infection or fever Antibody positive for Hepatitis C, HIV or TB Hepatic transaminases &gt; 2X normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>Alefacept</keyword>
</DOC>